RHOA MUTATION IS A POTENTIAL BIOMARKER ASSOCIATED WITH ADVERSE PROGNOSIS AND HIGH- TUMOR BURDEN IN PATIENTS WITH NODAL PERIPHERAL LYMPHOMAS WITH T-HELPER FOLLICULAR PHENOTYPE (NPTCL-THF): DATA FROM A BRAZILIAN RETROSPECTIVE COHORT OF NPTCL
2021 · Hematology Transfusion and Cell Therapy · 0 citations
https://doi.org/10.1016/j.htct.2021.10.172